Isatuximab, Bortezomib, Lenalidomide, and Limited Dexamethasone in Patients with Transplant-Ineligible Multiple Myeloma (REST): a Multicentre, Single-Arm, Phase 2 Trial.
The Lancet Haematology（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined